Business Context and Reporting Period
Company: TRxADE HEALTH, INC. (Note: Request metadata listed "Scienture Holdings, Inc.", but the filing is for TRxADE HEALTH, INC.)
Filing Type: Form 8-K (Current Report)
Date: February 15, 2022
Event: Entry into a Material Definitive Agreement and creation of a joint venture named SOSRx LLC with Exchange Health, LLC. SOSRx is a technology platform for pharmaceutical sales and purchases.
Key Financial Metrics and Obligations
This filing details a specific transaction structure rather than periodic financial results (revenue, profit, cash flow). Key financial terms include:
- Initial Cash Contribution: $325,000 contributed by TRxADE to SOSRx.
- Promissory Note: $500,000 issued by TRxADE to SOSRx and immediately assigned to Exchange Health.
- Interest Rate: Prime rate + 2% (currently 5.25% per annum).
- Repayment: One-third principal ($166,666.67) due Feb 15, 2023; remaining two-thirds payable quarterly over two years starting June 2023.
- Security: Non-recourse obligation secured solely by TRxADE's membership interests in SOSRx.
- Earn Out Payments: Up to $400,000 payable to Exchange Health based on SOSRx revenue and EBITDA targets for fiscal years 2022, 2023, and 2024.
- Payment Method: Cash or TRxADE common stock (at Company's discretion).
- Stock Cap: Maximum of 1,632,474 shares (approx. 19.99% of outstanding shares).
- Asset Contribution: Exchange Health contributed assets valued at $792,500 for its 49% interest and received a $275,000 cash payment from SOSRx.
- Distribution Fee: SOSRx to pay TRxADE's subsidiary (Integra) a fee of 2% of the net price of all product purchases.
Material Changes and Transaction Structure
The primary material change is the formation of SOSRx LLC, owned 51% by TRxADE and 49% by Exchange Health. This represents a strategic expansion into a pharmaceutical distribution platform. The transaction involves a mix of equity contribution, debt issuance, and contingent future payments (earn-outs) tied to the joint venture's performance.
Guidance, Risks, and Contingencies
- Performance Contingencies: Earn-out payments are strictly tied to SOSRx achieving specific revenue and EBITDA thresholds. If milestones are not met in a given year, no payment is due for that year, and they cannot be earned in subsequent years.
- Debt Cancellation Clause: If TRxADE effects a "Voluntary Withdrawal" from SOSRx prior to February 15, 2024, and SOSRx has failed to meet revenue targets, the remaining principal and interest on the Promissory Note are canceled.
- Default Provisions: Late payments on the Promissory Note incur additional interest fees (2% after 15 days, 3% after 30 days). Failure to pay within 60 days allows Exchange Health to declare the entire note immediately due.
- Management Control: TRxADE nominates 2 of 3 management committee members. If either party holds less than 25% interest, they forfeit management appointment rights.
- Forward-Looking Statements: The filing includes standard disclaimers regarding risks and uncertainties affecting future financial performance.
Investor Verification Checklist
- Verify the current trading price of TRxADE common stock to assess the potential dilution impact of the maximum 1,632,474 earn-out shares.
- Confirm the specific revenue and EBITDA targets for SOSRx for fiscal years 2022, 2023, and 2024 to evaluate the likelihood of earn-out payments.
- Review the "Non-Recourse" nature of the $500,000 Promissory Note to understand the extent of TRxADE's liability beyond its SOSRx equity stake.
- Monitor the 2% distribution fee revenue stream from Integra Pharma Solutions LLC to SOSRx.
- Check for any subsequent filings regarding the "Voluntary Withdrawal" clause and its potential to cancel debt obligations.